Verano Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Verano Holdings wird ein Gewinn- und Umsatzwachstum von 52.8% bzw. 5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 57.7% pro Jahr wachsen soll.

Wichtige Informationen

52.8%

Wachstumsrate der Gewinne

57.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	53.6%
Wachstumsrate der Einnahmen	5.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Are Investors Undervaluing Verano Holdings Corp. (CSE:VRNO) By 31%?

Oct 07

Why Investors Shouldn't Be Surprised By Verano Holdings Corp.'s (CSE:VRNO) 34% Share Price Surge

Sep 02

An Intrinsic Calculation For Verano Holdings Corp. (CSE:VRNO) Suggests It's 27% Undervalued

Jan 26

Verano Holdings Corp. (CSE:VRNO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 12

Verano Holdings' (CSE:VRNO) Earnings Are Weaker Than They Seem

May 25

Gewinn- und Umsatzwachstumsprognosen

NEOE:VRNO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	963	N/A	106	126	2
12/31/2025	921	-67	87	124	9
12/31/2024	879	-92	-15	95	10
9/30/2024	898	-146	6	101	N/A
6/30/2024	921	-122	60	108	N/A
3/31/2024	933	-113	86	124	N/A
12/31/2023	938	-117	73	110	N/A
9/30/2023	927	-256	70	106	N/A
6/30/2023	915	-281	43	91	N/A
3/31/2023	904	-278	-3	77	N/A
12/31/2022	879	-269	-25	94	N/A
9/30/2022	865	-60	-31	128	N/A
6/30/2022	844	-30	3	170	N/A
3/31/2022	819	-50	38	192	N/A
12/31/2021	738	-58	33	183	N/A
9/30/2021	600	-135	7	139	N/A
6/30/2021	458	-35	-19	86	N/A
3/31/2021	307	10	-20	77	N/A
12/31/2020	229	38	4	72	N/A
9/30/2020	179	127	5	73	N/A
12/31/2019	66	-18	-73	-7	N/A
12/31/2018	31	-1	-17	5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VRNO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VRNO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VRNO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VRNODie Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Canadian (7% pro Jahr).

Hohe Wachstumseinnahmen: VRNODie Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VRNO in 3 Jahren voraussichtlich hoch sein wird

Verano Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 50%

Consensus EPS estimates fall by 15%

Forecast to breakeven in 2026

Verano Holdings Corp. Provides Revenue Guidance for the Second Quarter 2024

Consensus EPS estimates fall by 32%

Consensus EPS estimates fall by 115%

Recent updates

Consensus EPS estimates fall by 50%

Third quarter 2024 earnings released: US$0.12 loss per share (vs US$0.052 loss in 3Q 2023)

New minor risk - Share price stability

Verano Commences Adult Use Cannabis Sales At Zen Leaf Waterbury in Connecticut

Verano Holdings Corp. to Report Q3, 2024 Results on Nov 07, 2024

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings released: US$0.063 loss per share (vs US$0.038 loss in 2Q 2023)

Verano Holdings Corp. Announces to Commence Adult Use Cannabis Sales in Ohio on August 6, 2024

Verano Holdings Corp. (NEOE:VRNO) has entered into equity purchase agreement to acquire Salubrious Wellness Clinic, Inc. from The Cannabist Company Holdings Inc. (OTCPK:CBST.F)

Verano Holdings Corp. to Report Q2, 2024 Results on Aug 07, 2024

Verano Holdings Corp. (NEOE:VRNO) announces an Equity Buyback for 17,320,857 shares, representing 5% for $50 million.

President notifies of intention to sell stock

Forecast to breakeven in 2026

Verano Holdings Corp. Provides Revenue Guidance for the Second Quarter 2024

Verano Holdings Corp. to Report Q1, 2024 Results on May 08, 2024

Verano Holdings Corp., Annual General Meeting, Jun 20, 2024

Verano Holdings Corp. announced delayed annual 10-K filing

Verano Holdings Corp. to Report Q4, 2023 Results on Feb 29, 2024

Verano Holdings Corp. Reimagines (the) Essence Brand and Introduces (the) Essence Nectar Line in Core Markets, Combining Bespoke Graphic Art and Terpene-Rich Full-Spectrum Cannabis Products

Consensus EPS estimates fall by 32%

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Verano Holdings Corp. Announces the Launch of Savvy Threads

Are Investors Undervaluing Verano Holdings Corp. (CSE:VRNO) By 31%?

Verano Holdings Corp. to Report Q3, 2023 Results on Nov 08, 2023

Now 21% undervalued

Why Investors Shouldn't Be Surprised By Verano Holdings Corp.'s (CSE:VRNO) 34% Share Price Surge

Consensus EPS estimates fall by 115%

New minor risk - Profitability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Verano Holdings Corp. Announces Executive Changes

New minor risk - Shareholder dilution

Verano Holdings Corp. to Report Q2, 2023 Results on Aug 08, 2023

Verano Holdings Corp Introduces On The Rocks, New Multi-Format Brand Anchored Around Solventless Extraction Methods, Across Core Markets

Verano Holdings Corp. Announces Executive Changes

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings released

Founder exercised options to buy CA$76k worth of stock.

Director recently sold CA$192k worth of stock

Director recently sold CA$81k worth of stock

Verano Holdings Corp. Announces Departure of Ed Brown from Its Board

Now 20% undervalued after recent price drop

An Intrinsic Calculation For Verano Holdings Corp. (CSE:VRNO) Suggests It's 27% Undervalued

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 28% undervalued after recent price drop

Chief Financial Officer recently sold CA$55k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Verano Holdings Corp. Launches BITS, Company's New Low-Dose, High-Function Edibles

Verano Holdings Corp. to Report Q3, 2022 Results on Nov 14, 2022

Goodness Growth Holdings, Inc. Commences Action in the Supreme Court of British Columbia Against Verano Holdings Corp

Verano Holdings Corp. (CNSX : VRNO) completed the acquisition of WSCC, Inc.

Verano Holdings Corp. Appoints Lawrence Hirsh as New Member of the Board of Directors and Chair of the Audit Committee

Verano Holdings Corp. announced delayed 10-Q filing

Verano Holdings Corp. Introduces New Flower and Extract Brand, Savvy, in Seven Core Cannabis Markets

Verano Holdings Corp. to Report Q2, 2022 Results on Aug 16, 2022

High number of new and inexperienced directors

Verano Holdings Corp., Annual General Meeting, Aug 03, 2022

Verano Holdings Corp. Announces the Reopening of Zen Leaf Canton in Its New Location At 3224 Cleveland Ave NW on April 4, 2022 At 10 A.M. Local Time

Verano Holdings Corp. to Report Q4, 2021 Results on Apr 07, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Verano Holdings Corp. (CNSX:VRNO) entered into a definitive arrangement to acquire Goodness Growth Holdings, Inc. (CNSX:GDNS) for approximately $300 million.

Verano Holdings Corp. (CNSX:VRNO) completed the acquisition of 100% equity interests in Connecticut Pharmaceutical Solutions, LLC from Tuatara Capital, L.P. and others.

Investor sentiment improved over the past week